Moomoo AI 已提取核心信息
On January 18, 2024, Incannex Healthcare Inc., a pharmaceutical company specializing in medicinal cannabinoid and psychedelic medicine therapies, announced the completion of dosing and treatment protocols for all participants in its PsiGAD-1 clinical trial. The trial, which took place at Monash University in Melbourne, Australia, involved 72 patients and is part of a Phase 2 study to evaluate the company's psilocybin treatment program for generalized anxiety disorder (GAD). The study aims to determine the efficacy of a 7-week psilocybin-assisted psychotherapy program compared to an active placebo. With safety and tolerability assessed, the trial also looks at secondary objectives of efficacy and quality of life. The interim analysis suggested a high probability of significant benefit for the psilocybin treatment over the placebo. Incannex is preparing an FDA IND application following the anticipated Q1 2024 topline results. Additionally, a documentary covering the Monash Clinical Psychedelic Lab and the PsiGAD research program is set to be released by the SBS television network in late February 2024.
On January 18, 2024, Incannex Healthcare Inc., a pharmaceutical company specializing in medicinal cannabinoid and psychedelic medicine therapies, announced the completion of dosing and treatment protocols for all participants in its PsiGAD-1 clinical trial. The trial, which took place at Monash University in Melbourne, Australia, involved 72 patients and is part of a Phase 2 study to evaluate the company's psilocybin treatment program for generalized anxiety disorder (GAD). The study aims to determine the efficacy of a 7-week psilocybin-assisted psychotherapy program compared to an active placebo. With safety and tolerability assessed, the trial also looks at secondary objectives of efficacy and quality of life. The interim analysis suggested a high probability of significant benefit for the psilocybin treatment over the placebo. Incannex is preparing an FDA IND application following the anticipated Q1 2024 topline results. Additionally, a documentary covering the Monash Clinical Psychedelic Lab and the PsiGAD research program is set to be released by the SBS television network in late February 2024.
2024年1月18日，专门从事药用大麻素和迷幻药物疗法的制药公司Incannex Healthcare Inc. 宣布完成了其psIGAD-1临床试验所有参与者的剂量和治疗方案。该试验在澳大利亚墨尔本的莫纳什大学进行，涉及72名患者，是评估该公司广泛性焦虑症（GAD）迷幻药治疗计划的2期研究的一部分。该研究旨在确定为期7周的迷幻药辅助心理治疗计划与活性安慰剂相比的疗效。通过评估安全性和耐受性，该试验还着眼于疗效和生活质量的次要目标。中期分析表明，与安慰剂相比，迷幻药治疗很有可能产生显著的益处。根据预期的2024年第一季度业绩，Incannex正在准备FDA的IND申请。此外，SBS电视网定于2024年2月下旬发布一部报道莫纳什临床迷幻实验室和PSIGad研究计划的纪录片。
2024年1月18日，专门从事药用大麻素和迷幻药物疗法的制药公司Incannex Healthcare Inc. 宣布完成了其psIGAD-1临床试验所有参与者的剂量和治疗方案。该试验在澳大利亚墨尔本的莫纳什大学进行，涉及72名患者，是评估该公司广泛性焦虑症（GAD）迷幻药治疗计划的2期研究的一部分。该研究旨在确定为期7周的迷幻药辅助心理治疗计划与活性安慰剂相比的疗效。通过评估安全性和耐受性，该试验还着眼于疗效和生活质量的次要目标。中期分析表明，与安慰剂相比，迷幻药治疗很有可能产生显著的益处。根据预期的2024年第一季度业绩，Incannex正在准备FDA的IND申请。此外，SBS电视网定于2024年2月下旬发布一部报道莫纳什临床迷幻实验室和PSIGad研究计划的纪录片。
有用
没用